There are 2789 resources available
877P - Comparison of dosimetric benefits in nasopharyngeal carcinoma patients among intensity-modulated radiotherapy, volumetric-modulated arc therapy and tomotherapy
Presenter: Wei Xiong
Session: ePoster Display
878P - Clinical profile and treatment outcomes of locally advanced carcinoma larynx treated with organ preservation approach: A retrospective analysis
Presenter: Afsar Fasaludeen
Session: ePoster Display
879P - Adaptive radiotherapy in head and neck cancer: A prospective dosimetric and volumetric study
Presenter: Apurva Pandey
Session: ePoster Display
880P - Systematic literature review (SLR) of randomized controlled trials in patients (pts) with newly diagnosed locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) ineligible for surgery
Presenter: Karthik Ramakrishnan
Session: ePoster Display
881P - Impact of neck dissection in N2-3 oropharyngeal squamous-cell carcinomas treated with definitive chemo-radiotherapy: An observational real-life study
Presenter: Guillaume Klausner
Session: ePoster Display
882P - Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer
Presenter: Lu Li
Session: ePoster Display
883P - Preliminary study of a new antibody marker anti-EBV BNLF2b in screening population in high-incidence areas of nasopharyngeal carcinoma
Presenter: Mingfang Ji
Session: ePoster Display
Resources:
Abstract
884P - Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Presenter: Susanne Flach
Session: ePoster Display
982P - A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer
Presenter: jing xie
Session: ePoster Display
983P - Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Presenter: Nuria Kotecki
Session: ePoster Display